Brief: Ipa’S Subsidiary Biostrand And Pgxai Announce Strategic Collaboration
25/06/2024 12:09
June 25 (Reuters) - Immunoprecise Antibodies Ltd
IPA.O :
* IPA’S SUBSIDIARY BIOSTRAND AND PGXAI ANNOUNCE STRATEGIC
COLLABORATION TO DEVELOP FIRST-IN-CLASS AI MODEL FOR
PHARMACOGENOMICS RECOMMENDATIONS USING LENSAI™
Source text for Eikon: ID:nBw21NSgXa
Further company coverage: IPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mindwalk Holdings
See all newsBrief: Mindwalk Holdings Corp. Announces Leadership Update
MindWalk Holdings Corp reports results for the quarter ended July 31 - Earnings Summary
Canada's MindWalk Q1 net loss widens on higher sales, marketing expenses
MindWalk Holdings Corp expected to post a loss of 8 cents a share - Earnings Preview
Brief: MindWalk Showcases Reefiq™ For Ai Drug Discovery At AMD Advancing Ai